New drug combo aims to outsmart HER2-Positive cancers
NCT ID NCT06364410
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a combination of two drugs—trastuzumab deruxtecan and azenosertib—in people with HER2-positive stomach, gastroesophageal junction, or other solid tumors that have spread or can't be removed by surgery. The goal is to find the safest dose and check for side effects. About 48 adults will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE III GASTRIC CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UT MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tracer that hunts unstable iron light up hidden tumors?
- Triple chemo cocktail aims to clear deadly bowel blockages in advanced stomach cancer
- Experimental drug combo targets Hard-to-Treat GI cancers
- Vaccine trains immune system to hunt down cancer cells
- Gut radiation may revive immunotherapy in resistant cancers
- One shot: could a single radiation dose control metastatic cancer?